Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mesa LaboratoriesMLAB -3.42%77 3-Year EBITDA Growth Rate is 5.70% as of Mar. 2026, which is 48% below its 10-year median of 11.00. GuruFocus rates MLAB with a GF Score™ of 77/100 and a GF Value™ of $116.37 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 2,031 Hardware companies, Mesa Laboratories ranks better than 57.36% on this metric.
During the past 12 months, Mesa Laboratories's average EBITDA Per Share Growth Rate was 5.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 5.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Mesa Laboratories was 96.40% per year. The lowest was -19.40% per year. And the median was 11.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Mesa Laboratories 3-Year EBITDA Growth Rate Related Terms
MLAB vs AERG, USBC, MVIS: 3-Year EBITDA Growth Rate Comparison
For the Scientific & Technical Instruments subindustry, Mesa Laboratories's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mesa Laboratories 3-Year EBITDA Growth Rate vs Hardware Industry
For the Hardware industry and Technology sector, Mesa Laboratories's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Mesa Laboratories's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 5.70% mean?
Mesa Laboratories (MLAB) has a 3-Year EBITDA Growth Rate of 5.70% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Mesa Laboratories and its competitors. This is 48% below median its historical median of 11.00. According to the industry distribution chart, Mesa Laboratories ranks #866 out of 2031 companies in the Hardware industry, placing it in the top 42.6%.
Is Mesa Laboratories' 3-Year EBITDA Growth Rate too high?
Mesa Laboratories' current 3-Year EBITDA Growth Rate of 5.70% is 48% below median its 10-year median of 11.00. The Hardware industry median 3-Year EBITDA Growth Rate is 1.60. Mesa Laboratories' value of 5.70% is 256.3% above this industry median. Based on the distribution chart, Mesa Laboratories ranks #866 out of 2031 companies in the Hardware industry, which is above the industry midpoint. Overall, Mesa Laboratories has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mesa Laboratories' 3-Year EBITDA Growth Rate compare to AERG and USBC?
According to the Hardware industry distribution chart, Mesa Laboratories ranks #866 out of 2031 companies for 3-Year EBITDA Growth Rate. This puts Mesa Laboratories in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 1.60. Mesa Laboratories' value of 5.70% is 256.3% above this benchmark. While the company's 10-year median is 11.00 vs. the industry median of 1.60, Mesa Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Hardware company?
The median 3-Year EBITDA Growth Rate among Hardware companies is 1.60, based on 2,031 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mesa Laboratories's current 3-Year EBITDA Growth Rate of 5.70% is 256.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Mesa Laboratories and its competitors. For the Hardware industry, the median 3-Year EBITDA Growth Rate is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mesa Laboratories's current 3-Year EBITDA Growth Rate is 5.70%, which is 48% below median its own 10-year median of 11.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesa Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Mesa Laboratories (MLAB) is currently considered Modestly Undervalued. The stock's GF Value™ is $116.37, compared to a current price of $97.72 — trading 16% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 5.70%, which is 48% below median its 10-year median of 11.00 and 256.3% above the Hardware industry median of 1.60. Mesa Laboratories' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Mesa Laboratories (MLAB), the current 3-Year EBITDA Growth Rate is 5.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mesa Laboratories (MLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Mesa Laboratories stock appears to be undervalued.
The current stock price of $97.72 is trading 16% below its estimated GF Value™ of $116.37.
GuruFocus considers Mesa Laboratories to be Modestly Undervalued.
Key valuation signals for MLAB:
3-Year EBITDA Growth Rate: 5.70% (48% below median its 10-year median of 11.00)
GF Value™: $116.37 vs. price of $97.72 (16% below fair value)
Industry Position: 256.3% above the Hardware median (#866 of 2031)
No single metric tells the full story. See the MLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
77GF Score
Get the complete analysis for MLAB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLAB has been successfully added to your 
